-
-
-
-
-
-
-
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
-
-
-
-
-
-
-
PureTech reports positive data from cancer drug trial
-
-
-
-
-
-
-
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
-
-
-
-
-
-
-
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
-
-
-
-
-
-
-
PureTech Announces Annual Results for Year Ended December 31, 2023
-
-
-
-
-
-
-
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
-
-
-
-
-
-
-
PureTech Health-Founded (PRTC) Akili Interactive Reports Publication of Data Demonstrating its Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults w/ Major Depressive Disorder When Co
-
68,105 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

